Cowen and Company’s Sage Therapeutics SAGE Stock Holding History

Cowen and Company’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-18,000	Closed	-$120K	–	513
2019 Q4	$120K	Buy	+18,000	New	+$2.21M	0.01%	251

Other funds holding SAGE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return

Cowen and Company's SAGE Position: Q4 2024 in Review

Cowen and Company sold out of Sage Therapeutics (SAGE) in Q4 2024, closing a stake of 161,186 shares — an estimated $1.16M sold.

Cowen and Company first reported a position in SAGE in Q4 2023 and held it in 4 quarters. The position peaked at $29M in Q4 2023. 177 funds tracked by Wall St. Rank hold SAGE as of Q4 2024.

Cowen and Company reported no remaining Sage Therapeutics position as of Q4 2024 after selling out during the quarter.
Cowen and Company sold 161,186 Sage Therapeutics shares in Q4 2024, an estimated $1.16M.
Cowen and Company first reported a position in Sage Therapeutics in Q4 2023 and held it in 4 quarters.
Cowen and Company's Sage Therapeutics position peaked at $29M in Q4 2023.
177 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2024.

Based on Cowen and Company's 13F filing for Q4 2024.